Tag «CANCER»

FDA approves third oncology drug Rozlytrek (entrectinib) that targets a key genetic driver of cancer, rather than a specific type of tumor

It’s only fair to share… FDA approves third oncology drug Rozlytrek (entrectinib) that targets a key genetic driver of cancer, rather than a specific type of tumor  FDA also approves drug for second indication in a type of lung cancer The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for …

CC-90009

It’s only fair to share… CC-90009 CC-90009-AML-001 CAS 1860875-51-9 461.8 g/mol, C22H18ClF2N3O4 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide 4-Chloro-N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-α,α-difluorobenzeneacetamide Benzeneacetamide, 4-chloro-N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-α,α-difluoro- Phase 1 Clinical, Acute myelogenous leukemia, Protein cereblon modulator Useful for treating chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia or acute myeloid leukemia. Celgene is developing CC-90009, a cereblon E3 ligase modulator, for treating AML; in January 2019, data from a …

Selinexor

It’s only fair to share…   Selinexor セリネクソル KPT-330 UNII-31TZ62FO8F (Z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-N‘-pyrazin-2-ylprop-2-enehydrazide Formula C17H11F6N7O CAS 1393477-72-9 Mol weight 443.306 FDA, APPROVED 2019/7/3, Xpovio CAS : 1393477-72-9 (free base)   1421923-86-5 (E-isomer)   1621865-82-4 (E-isomer)   Unknown (HCl) Treatment of cancer, Antineoplastic, Nuclear export inhibitor Selinexor (INN, trade name Xpovio; codenamed KPT-330) is a selective inhibitor of nuclear export used as an anti-cancer drug. It works by quasi-irreversibly binding to exportin …

Picropodophyllin

It’s only fair to share… Picropodophyllin Picropodophyllotoxin CAS 477-47-4 AXL1717, NSC 36407, BRN 0099161 414.4 g/mol, C22H22O8 (5R,5aR,8aS,9R)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Furo(3′,4′:6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5R-(5-alpha,5a-alpha,8a-alpha,9-alpha))- 5-19-10-00665 (Beilstein Handbook Reference) Axelar is developing picropodophyllin, a small-molecule IGF-1 receptor antagonist for the treatment of cancer including NSCLC and malignant astrocytoma. In February 2019, a phase Ia study was planned to initiate for solid tumor …

HS-10340

It’s only fair to share…   HS-10340 CAS 2156639-66-4 MF C26 H31 N7 O5 MW 521.57 1,8-Naphthyridine-1(2H)-carboxamide, N-[5-cyano-4-[[(1R)-2-methoxy-1-methylethyl]amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(tetrahydro-2-oxo-1,3-oxazepin-3(2H)-yl)methyl]- (R)-N-(5-cyano-4-((1-methoxypropan-2-yl)amino)pyridin-2-yl)-7-formyl-6-((2-carbonyl)-1,3-oxazepine-3-yl)methyl)-3,4-dihydro-1,8-naphthyridin-1(2H)-carboxamide CAS 2307670-65-9 Jiangsu Hansoh Pharmaceutical Group Co Ltd Being investigated by Jiangsu Hansoh, Shanghai Hansoh Biomedical and Changzhou Hengbang Pharmaceutical ; in June 2018, the product was being developed as a class 1 chemical drug in China. Useful for treating liver cancer, gastric …

GFH-018

It’s only fair to share… GFH-018 CAS 2169299-67-4 C21 H19 N7 O, 385.42 (E)-3-[6-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-[1,2,4]triazolo[1,5-a]pyridin-5-yl]prop-2-enamide 2-Propenamide, 3-[6-[5,6-dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl][1,2,4]triazolo[1,5-a]pyridin-5-yl]-, (2E)- GenFleet Therapeutics Advanced solid tumor; Cancer TGF-beta Receptor Type-1 (TGFBR1; ALK5; SKR4; TbetaR-I) Inhibitors Signal Transduction Modulators GFH-018 , a TGFBR1 inhibitor, being investigated by GenFleet as an oral tablet formulation, for the treatment of cancer, including advanced solid tumors and hepatocellular carcinoma,  …

SEVITERONEL, севитеронел , سيفيتيرونيل , 赛维罗奈 ,

It’s only fair to share… SEVITERONEL CAS Registry Number 1610537-15-9 Molecular formulaC18 H17 F4 N3 O3, MW 399.34 1H-1,2,3-Triazole-5-methanol, α-[6,7-bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-, (αS)- (αS)-α-[6,7-Bis(difluoromethoxy)-2-naphthalenyl]-α-(1-methylethyl)-1H-1,2,3-triazole-5-methanol 8S5OIN36X4 севитеронел [Russian] [INN] سيفيتيرونيل [Arabic] [INN] 赛维罗奈 [Chinese] [INN] Mechanism of ActionAndrogen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors; Steroid 17-alpha-hydroxylase modulators WHO ATC codeL01 (Antineoplastic Agents)L01X-X (Other antineoplastic agents) EPhMRA codeL1 (Antineoplastics)L1X9 (All other antineoplastics) 1H-1,2,3-Triazole-5-methanol, alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (alphaS)- …

Talazoparib, MDV3800

It’s only fair to share… Talazoparib, BMN-673, MDV-3800 (2S,3S)-methyl-7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one CAS 1207456-01-6 Chemical Formula: C19H14F2N6O Exact Mass: 380.11972 BMN673, BMN673, BMN-673, LT673, LT 673, LT-673,  Talazoparib BioMarin Pharmaceutical Inc phase 3 Poly ADP ribose polymerase 2 inhibitor; Poly ADP ribose polymerase 1 inhibitor cancer (85,9R)-5-fluoro-8-(4-fluorophenyl)-9-(l-methyl-lH-l,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one toluenesulfonate salt CAS 1373431-65-2(Talazoparib Tosylate) 1H NMR DMSOD6 13C NMR DMSOD6 HMBC …

Biocon Launches KRABEVA® in India, A Biosimilar Bevacizumab for Treating Several Types of Cancer

It’s only fair to share… Biocon Launches KRABEVA® in India,  A Biosimilar Bevacizumab for Treating Several Types of Cancer On November 23, 2017, Biocon India’s premier Biopharmaceuticals Company announced that it has launched KRABEVA®, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, …

FDA approves first biosimilar Herceptin (trastuzumab) for the treatment of certain breast and stomach cancers

It’s only fair to share… FDA approves first biosimilar for the treatment of certain breast and stomach cancers Ogivri, a biosimilar to the cancer drug Herceptin, is approved for HER2+ breast cancer and metastatic stomach cancers The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment …